pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib
Sun Yat-sen University
Sun Yat-sen University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Safety of Almonertinib, Subjects With Hyperuricemia, Renal Function Disorder, Acute-O
Company details
- Status
- Public
- HQ
- 广州市新港西路135号, CN
- Employees
- 3,680
- Programs
- 19
- Drugs
- 25
- Patents
- 0
Cytokine-Induced Killer Cells
Phase 3 · mab · Carcinoma, Hepatocellular
Cytokine-Induced Killer Cells for Carcinoma, Hepatocellular is a Phase 3 program (mab) at Sun Yat-sen University with 1 ClinicalTrials.gov record(s).
Internal code 2007043-HCC012
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sun Yat-sen University
- Phase
- Phase 3
- Modality
- mab
- Indication
- Carcinoma, Hepatocellular
- Status
- completed
- Trials
- 1